Medical News Today -- An article published Online First and in the October edition of The Lancet Oncology reports that the blood-thinning drug nadroparin halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy. Consequently, it could become an important preventive treatment in these patients.
